Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.44 |
| ▸ | SMO | Q99835 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436720 | 0.77 | MALT1 (0.45) | MALT1SMOKMT2ATRPV1ELANE | |
| SCHEMBL3436718 | 0.76 | MALT1 (0.46) | MALT1KMT2AAOC3TRPV1ELANE | |
| SCHEMBL238160 | 0.76 | KDM4E (0.60) | MALT1KMT2ATRPV1ELANEKDM4E | |
| SCHEMBL3436393 | 0.75 | KDM4E (0.66) | MALT1KMT2ATRPV1ELANEPDE10A | |
| SCHEMBL3436730 | 0.75 | TRPV1 (0.52) | MALT1SMOKMT2ATRPV1 | |
| SCHEMBL3436582 | 0.75 | POLB (0.52) | MALT1SMOKMT2ATRPV1 | |
| SCHEMBL3436733 | 0.74 | MALT1 (0.53) | MALT1SMOTRPV1KDM4E | |
| SCHEMBL13939912 | 0.74 | CCR5 (0.44) | MCHR1HRH3VNN1CCR5 | |
| SCHEMBL17598999 | 0.72 | ADRB3 (0.56) | KMT2A | |
| SCHEMBL15962970 | 0.72 | TRPV1 (0.49) | MALT1SMOKMT2ATRPV1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | MALT1 1638/4885SMO 1636/4885MCHR1 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.